Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 Black Phoenix Black Phoenix +30.57%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.47%
#4 Palladium Network Palladium Network +17.37%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.32%
#6 Fake World Assets Fake World Assets +14.46%
#7 clBTC clBTC +12.22%
#8 Akedo Akedo +12.02%
#9 Pons Pons +10.03%
#10 Arowana Arowana +10.03%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Clasificación en acciones #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Precio por acción
$0.00366968
Última sincronización: 2024-07-23
Capitalización bursátil
$291.42K
Cambio (1 día)
-0.81%
Cambio (1 año)
0.00%
País
US
Comercio Bioasis Technologies Inc. (BTI)

Categoría

Healthcare
Margen Operativo de Bioasis Technologies Inc. (BTI)
Margen Operativo al 2026 TTM: 0.00%
Según los informes financieros más recientes y el precio de las acciones de Bioasis Technologies Inc., el margen operativo actual (TTM) es 0.00%. Al final de 2026, el margen operativo era 0.00%.
Historial de Margen Operativo de Bioasis Technologies Inc. desde 2026 hasta 2026
Margen Operativo al final de cada año
Año Margen Operativo Cambiar
Not enough data for the provided dates.
Margen Operativo de empresas similares o competidoras
Empresa Margen Operativo Diferencia de Margen Operativo País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.